Vehicle for myopia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Feb 2023: Trial registered, NCT05728944
  2. 21 Feb 2023: Trial started, NCT05753189
  3. 3 Mar 2023: Trial registered, NCT05753189
  4. 6 Mar 2023: Trial started, NCT05728944

The trials

NCT05728944: Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

State
Completed
Phase
Phase 3
People
229 taking part
Started
6 Mar 2023
Primary completion
14 Dec 2023
Arms
Vehicle Ophthalmic Solution dosed bilaterally
Results
Posted on the registry
  1. 15 Feb 2023: Trial registered
  2. 6 Mar 2023: Trial started
  3. 24 Jan 2024: Trial completed
  4. 25 Feb 2026: Trial results posted

NCT05753189: Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

State
Completed
Phase
Phase 3
People
362 taking part
Started
21 Feb 2023
Primary completion
9 Feb 2024
Arms
Vehicle Ophthalmic Solution dosed bilaterally
Results
Posted on the registry
  1. 21 Feb 2023: Trial started
  2. 3 Mar 2023: Trial registered
  3. 9 Feb 2024: Trial completed
  4. 13 May 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.